FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280492281> ?p ?o ?g. }

• W4280492281 endingPage "1551" @default.
• W4280492281 startingPage "1541" @default.
• W4280492281 abstract "Dupilumab has demonstrated a great reduction in chronic pruritus that is the hallmark of atopic dermatitis (AD). Underscoring relevant pathogenesis similarities emerging from AD, chronic idiopathic pruritus (CIP) and chronic prurigo (CP), several authors suggested the beneficial role of dupilumab in these conditions. The evidence on this subject is limited with no precise data available. In this study, we carried out a systematic literature review in order to evaluate the efficacy of dupilumab on both pruritus and skin manifestations in the two largest retrospective cohorts of patients with CP and CIP and tried to identify potential response predictors. Electronic searches were conducted on 4 databases. Our primary outcome was the improvement in pruritus measured by a reduction in the patient's reported numerical rating scale of itch (NRSI) by >4. Secondary outcomes included the proportion of patients with a complete response at the end of treatment, reduction in the number of lesions by the Investigator Global Assessment (IGA), improvement in numerical rating scale of sleep (NRSS), improvement in quality of life measured by the Dermatology Life Quality Index (DLQI), time until patient perceived any improvement (Time-First) and time until the patient-reported absence of pruritus (Time-Final). Descriptive statistics were calculated for each demographic and clinical variable. Univariate logistic regression analyses were conducted to explore the association between response to dupilumab and potential predictive factors. We included 25 articles in the analysis, counting a total of 153 patients. Based on CP patients' cohort (n = 132), the mean NRSI at baseline was 8.79 ± 0.86 and the NRSI final was 2.32 ± 1.27. The mean time to first improvement was 5.18 ± 3.13 weeks, while the time to complete improvement of pruritus (Time-final) was 13.6 ± 12.0 weeks. Ninety patients out of 109 (83%) noticed an improvement in pruritus before 4 weeks of dupilumab therapy. At the end of treatment, 18 patients out of 126 (14%) had a complete remission of pruritus and 110 patients out of 123 (89%) had a reduction of NRSI >4. The reduction in NRSI was significantly greater in patients improving before 4 weeks of treatment (6.57 ± 1.71) compared with patients improving in more than 4 weeks (5.49 ± 1.39, P < 0.001). Patients with history of AD and those who have been previously treated with cyclosporine or methotrexate had a significantly lower reduction in NRSI (e.g. 6.05 ± 1.34 vs. 7.08 ± 1.90, P < 0.01 for nonassociated AD patients). Based on CIP patient's cohort (n = 21), the mean NRSI at baseline was 8.33 ± 0.80 and the NRSI final was 0.95 ± 0.59. The mean time to first improvement was 2 ± 0 weeks, while the time to complete improvement (Time-final) was 14.6 ± 10 weeks. At the end of treatment, 3 patients out of 21 (14%) had a complete remission of pruritus and 100% of patients had a reduction of NRSI >4. No serious treatment-emergent adverse events were reported. The most common adverse event was mild conjunctivitis (13 cases). We highlight the importance of one early sign of improvement as a predictor of the future response to dupilumab: the improvement before 4 weeks of treatment that leads significantly to a greater final reduction in NRSI. Furthermore, patients with the presence or history of atopy appear to be less responsive to dupilumab than nonatopic patients and develop more side effects, in particular conjunctivitis." @default.
• W4280492281 created "2022-05-22" @default.
• W4280492281 creator A5004405224 @default.
• W4280492281 creator A5026420254 @default.
• W4280492281 creator A5048718981 @default.
• W4280492281 creator A5066890380 @default.
• W4280492281 date "2022-05-31" @default.
• W4280492281 modified "2023-10-18" @default.
• W4280492281 title "Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors" @default.
• W4280492281 cites W1491767948 @default.
• W4280492281 cites W1537248210 @default.
• W4280492281 cites W1989729255 @default.
• W4280492281 cites W2032062642 @default.
• W4280492281 cites W2043956972 @default.
• W4280492281 cites W2077529892 @default.
• W4280492281 cites W2118630839 @default.
• W4280492281 cites W2524051065 @default.
• W4280492281 cites W2610814011 @default.
• W4280492281 cites W2748617188 @default.
• W4280492281 cites W2752706812 @default.
• W4280492281 cites W2753646323 @default.
• W4280492281 cites W2771011851 @default.
• W4280492281 cites W2801759342 @default.
• W4280492281 cites W2809126209 @default.
• W4280492281 cites W2809640877 @default.
• W4280492281 cites W2900829447 @default.
• W4280492281 cites W2901974522 @default.
• W4280492281 cites W2904101791 @default.
• W4280492281 cites W2917742554 @default.
• W4280492281 cites W2924758607 @default.
• W4280492281 cites W2936340152 @default.
• W4280492281 cites W2941471437 @default.
• W4280492281 cites W2953563973 @default.
• W4280492281 cites W2953922585 @default.
• W4280492281 cites W2959876937 @default.
• W4280492281 cites W2969363587 @default.
• W4280492281 cites W2972531102 @default.
• W4280492281 cites W2972826485 @default.
• W4280492281 cites W2973437633 @default.
• W4280492281 cites W2973441550 @default.
• W4280492281 cites W2996651691 @default.
• W4280492281 cites W2997637589 @default.
• W4280492281 cites W3000262597 @default.
• W4280492281 cites W3007825879 @default.
• W4280492281 cites W3008008049 @default.
• W4280492281 cites W3013281025 @default.
• W4280492281 cites W3022882322 @default.
• W4280492281 cites W3026551947 @default.
• W4280492281 cites W3031381195 @default.
• W4280492281 cites W3035811381 @default.
• W4280492281 cites W3037309233 @default.
• W4280492281 cites W3078033824 @default.
• W4280492281 cites W3086151842 @default.
• W4280492281 cites W3104928113 @default.
• W4280492281 cites W3105365921 @default.
• W4280492281 cites W3109102374 @default.
• W4280492281 cites W3109412917 @default.
• W4280492281 cites W3128570647 @default.
• W4280492281 cites W3135226336 @default.
• W4280492281 cites W3138228045 @default.
• W4280492281 cites W3148672544 @default.
• W4280492281 doi "https://doi.org/10.1111/jdv.18221" @default.
• W4280492281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35569006" @default.
• W4280492281 hasPublicationYear "2022" @default.
• W4280492281 type Work @default.
• W4280492281 citedByCount "10" @default.
• W4280492281 countsByYear W42804922812022 @default.
• W4280492281 countsByYear W42804922812023 @default.
• W4280492281 crossrefType "journal-article" @default.
• W4280492281 hasAuthorship W4280492281A5004405224 @default.
• W4280492281 hasAuthorship W4280492281A5026420254 @default.
• W4280492281 hasAuthorship W4280492281A5048718981 @default.
• W4280492281 hasAuthorship W4280492281A5066890380 @default.
• W4280492281 hasConcept C126322002 @default.
• W4280492281 hasConcept C138496976 @default.
• W4280492281 hasConcept C144301174 @default.
• W4280492281 hasConcept C151956035 @default.
• W4280492281 hasConcept C15744967 @default.
• W4280492281 hasConcept C159110408 @default.
• W4280492281 hasConcept C16005928 @default.
• W4280492281 hasConcept C167135981 @default.
• W4280492281 hasConcept C1862650 @default.
• W4280492281 hasConcept C205545832 @default.
• W4280492281 hasConcept C2776173921 @default.
• W4280492281 hasConcept C2778329239 @default.
• W4280492281 hasConcept C2779134260 @default.
• W4280492281 hasConcept C2779824493 @default.
• W4280492281 hasConcept C2779951463 @default.
• W4280492281 hasConcept C2780699399 @default.
• W4280492281 hasConcept C38180746 @default.
• W4280492281 hasConcept C71924100 @default.
• W4280492281 hasConcept C72563966 @default.
• W4280492281 hasConcept C83849319 @default.
• W4280492281 hasConceptScore W4280492281C126322002 @default.
• W4280492281 hasConceptScore W4280492281C138496976 @default.
• W4280492281 hasConceptScore W4280492281C144301174 @default.
• W4280492281 hasConceptScore W4280492281C151956035 @default.
• W4280492281 hasConceptScore W4280492281C15744967 @default.

• next